

Supplemental online content for:

Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ

Michael J. Hassett, MD, MPH; Wei Jiang, MS; Melissa E. Hughes, MSc; Stephen Edge, MD; Sara H. Javid, MD; Joyce C. Niland, PhD; Richard Theriault, MD; Yu-Ning Wong, MD; Deborah Schrag, MD; and Rinaa S. Punglia, MD, MPH

J Natl Compr Canc Netw 2018;16(4):387–394

eTable 1: Independent Determinants of AET for the Initial DCIS

eTable 2: Independent Determinants of SBE

eTable 3: Use of AET for Initial DCIS and SBE

eTable 1. Independent Determinants of AET for the Initial DCIS		
Characteristics	OR (95% CI)	P Value
Age at recurrence, y		.0003
<50	1.5 (1.2–1.9)	
50 to <60	1.4 (0.9–2.1)	
≥60	Ref	
Comorbidity score		.0102
0	Ref	
≥1	0.7 (0.6–0.9)	
Year of DCIS diagnosis		.3163
1997–2000	Ref	
2001–2004	1.3 (0.8–2.0)	
2005–2008	1.2 (0.6–2.3)	
Pathologic size, cm		.1306
0 to <1	Ref	
1 to <2	0.8 (0.6–1.1)	
≥2	0.6 (0.3–1.2)	
Unknown	1.1 (0.8–1.6)	
Margin distance		.0873
Negative	Ref	
Positive	2.1 (0.9–4.9)	
Hormone receptor status		<.0001
Positive	Ref	
Negative	0.2 (0.1–0.5)	
Unknown	1.3 (0.7–2.6)	
Radiation therapy for DCIS		.0002
No	Ref	
Yes	1.7 (1.3–2.3)	

Abbreviations: AET, antiestrogen therapy; DCIS, ductal carcinoma in situ; OR, odds ratio.

eTable 2. Independent Determinants of SBE		
Clinical Characteristics	OR (95% CI)	P Value
Age at initial DCIS, y		.33
<50	Ref	
50 to <60	1.06 (0.75–1.49)	
≥60	1.38 (0.89–2.14)	
Race/Ethnicity		.67
White non-Hispanic	Ref	
Nonwhite/Hispanic	1.08 (0.77–1.51)	
Menopausal status		<.01
Premenopausal	Ref	
Postmenopausal	0.43 (0.23–0.79)	
Body mass index, kg/m ²		.50
<25	Ref	
≥25	1.04 (0.76–1.42)	
Unknown	1.22 (0.88–1.69)	
Comorbidity score		.58
0	Ref	
≥1	1.09 (0.81–1.46)	
Initial year of DCIS diagnosis		.24
1997–2000	Ref	
2001–2004	0.91 (0.67–1.23)	
2005–2008	0.61 (0.34–1.11)	
Initial DCIS presentation		.94
Mammography	Ref	
Symptomatic	1.02 (0.68–1.52)	
Initial DCIS pathologic size, cm		<.01
0 to <1	Ref	
1 to <2	1.2 (0.64–2.24)	
≥2	2.18 (1.5–3.17)	
Unknown	1.21 (0.76–1.92)	
Initial DCIS margin		.44
Positive	Ref	
Negative	0.8 (0.45–1.41)	
Initial DCIS grade		.39
Low	Ref	
Intermediate	1.53 (0.94–2.47)	
High	1.41 (0.8–2.51)	
Other/Unknown	1.5 (0.79–2.84)	
Initial DCIS subtype		<.01
Comedo	Ref	
Noncomedo	0.79 (0.52–1.2)	
Unknown/Missing	0.30 (0.14–0.64)	
Initial DCIS hormone receptor status		<.01
Positive	Ref	
Negative	2.81 (2.11–3.74)	
Unknown/Missing	1.67 (1.23–2.28)	
Initial DCIS radiation therapy		<.01
Yes	Ref	
No	2.38 (1.73–3.26)	
Initial DCIS antiestrogen therapy		.26
Any	Ref	
None	1.11 (0.93–1.32)	

Abbreviations: DCIS, ductal carcinoma in situ; OR, odds ratio; SBE, second breast event.

eTable 3. Use of AET for Initial DCIS and SBE		
AET for SBE	AET for Initial DCIS n (section %)	No AET for Initial DCIS n (section %)
All recurrences (N=200)		
Yes	31 (16)	24 (12)
No	41 (20)	104 (52)
Invasive HR-positive/unknown recurrences (N=71)		
Yes	14 (20)	14 (20)
No	21 (30)	22 (31)
Noninvasive HR-positive/unknown recurrences (N=98)		
Yes	14 (14)	10 (10)
No	15 (15)	59 (60)
All HR-negative recurrences (N=31)		
Yes	3 (10)	0 (0)
No	5 (16)	23 (74)

Abbreviations: AET, antiestrogen therapy; DCIS, ductal carcinoma in situ; HR, hormone receptor; SBE, second breast event.